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Rare germline variants in DNA repair genes and the
angiogenesis pathway predispose prostate cancer patients to
develop metastatic disease
Martina Mijuskovic1, Edward J. Saunders1, Daniel A. Leongamornlert1, Sarah Wakerell1, Ian Whitmore1, Tokhir Dadaev1,
Clara Cieza-Borrella1, Koveela Govindasami1, Mark N. Brook1, Christopher A. Haiman2, David V. Conti2, Rosalind A. Eeles1,3 and
Zsoﬁa Kote-Jarai1
BACKGROUND: Prostate cancer (PrCa) demonstrates a heterogeneous clinical presentation ranging from largely indolent to lethal.
We sought to identify a signature of rare inherited variants that distinguishes between these two extreme phenotypes.
METHODS:We sequenced germline whole exomes from 139 aggressive (metastatic, age of diagnosis < 60) and 141 non-aggressive
(low clinical grade, age of diagnosis ≥60) PrCa cases. We conducted rare variant association analyses at gene and gene set levels
using SKAT and Bayesian risk index techniques. GO term enrichment analysis was performed for genes with the highest differential
burden of rare disruptive variants.
RESULTS: Protein truncating variants (PTVs) in speciﬁc DNA repair genes were signiﬁcantly overrepresented among patients with
the aggressive phenotype, with BRCA2, ATM and NBN the most frequently mutated genes. Differential burden of rare variants was
identiﬁed between metastatic and non-aggressive cases for several genes implicated in angiogenesis, conferring both deleterious
and protective effects.
CONCLUSIONS: Inherited PTVs in several DNA repair genes distinguish aggressive from non-aggressive PrCa cases. Furthermore,
inherited variants in genes with roles in angiogenesis may be potential predictors for risk of metastases. If validated in a larger
dataset, these ﬁndings have potential for future clinical application.
British Journal of Cancer (2018) 119:96–104; https://doi.org/10.1038/s41416-018-0141-7
INTRODUCTION
Prostate cancer (PrCa) is the most common malignancy diagnosed
in men living in the developed world and responsible for over
250,000 deaths per year worldwide.1 Family history is a strong risk
factor for the disease, with twin studies conﬁrming a large
contribution by genetic factors.2,3 The majority of PrCa cases are
diagnosed with intermediate risk disease, although an appreciable
number of individuals develop metastatic disease with low survival
rates.4,5 In order to simultaneously limit overtreatment whilst
ensuring early diagnosis of potentially aggressive and lethal cases,
it is critical to identify genetic factors predictive of clinical outcome.
Few heritable factors predictive of aggressive PrCa have been
identiﬁed to date. Although common variants identiﬁed thus far
explain over a quarter of the familial relative risk of PrCa,6 GWAS
subset analysis of aggressive disease has failed to ﬁnd loci
speciﬁcally associated only with the aggressive phenotype.7 We
have previously presented evidence that BRCA2 is a moderate
penetrance gene contributing to young-onset disease with a
signiﬁcantly more aggressive clinical course.8–10 Furthermore, loss
of function mutations in a small number of additional DNA repair
genes have been demonstrated to predispose to familial PrCa and
are associated with more aggressive phenotypes including
metastatic disease.11–13
We hypothesised that additional rare germline variants exist
that are predictive of poorer prognosis and could improve clinical
management of the disease. However, due to the large number of
neutral rare germline variants carried by each individual, detection
of causative variants is challenging. In an attempt to enrich for rare
variants that predispose to the aggressive disease outcome, we
designed a case–case study that sampled the extremes of the PrCa
phenotype. Our cohort compared young onset, metastatic
patients against cases with older onset, indolent disease. We
performed whole exome sequencing to identify genes and
biological processes with the highest differential burden of
disruptive rare variants, which may in turn represent a signature
of aggressiveness.
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MATERIALS AND METHODS
Study design and sequencing
Germline DNA samples for 144 aggressive (metastatic, diagnosed
age<60) and 144 non-aggressive (Gleason score <7, tumour stage
T1-2b, no nodal spread or metastases, diagnosed age ≥60) PrCa
cases from the UK Genetic Prostate Cancer Study (UKGPCS)14
were obtained from whole blood and distributed on three 96-well
plates for DNA library preparation and sequencing. To minimise
any potential for case–case confounding caused by batch effects,
samples were block randomised based on case status and DNA
extraction method. DNA samples were fragmented using a
Covaris E220 Ultrasonicator and exome sequences enriched
using Agilent SureSelectXT2 Human All Exon V5 baits, in 36
pools (8 samples/pool) using 7 bp molecular barcodes. Pools were
sequenced on an Illumina HiSeq 2500 instrument (v4 chemistry,
2 × 100 bp reads).
Variant calling and annotation
Paired end reads were adaptor-masked using Cutadapt 1.515 and
aligned to the GRCh37/hg19 reference genome using BWA-MEM
0.7.10.16 Variants were jointly called across all samples using GATK
3.5,17 following the speciﬁed best practices (https://software.
broadinstitute.org/gatk/best-practices/). Analysis was restricted to
the exome capture regions plus additional 100 bp padding.
Variant annotation was performed using wAnnovar,18 Oncotator
1.819 and WGSA20 (Amazon EC2 cloud, AWS community instance:
WGSA055-ubuntu-800G). Combined Annotation Dependent
Depletion (CADD) scores21 were used to predict deleteriousness
of single nucleotide variants and indels. Transcript annotation was
taken from the Oncotator pipeline using the transcript list giving
priority to known clinical protein changes (Feb 2016). GENCODE
(Version 19 - July 2013 freeze, GRCh37 - Ensembl 74) was used as
the reference transcript set.
Variant ﬁltering and sample quality control
Prior to genotype calling, samples were assessed for sufﬁcient
coverage (>80% of bases at ≥20 × sequencing depth) and low
contamination ( <10%), as estimated by VerifyBamID 1.1.22
Samples not achieving these quality thresholds were excluded
from further analysis (Supplementary Table 1). After genotype
calling, variant quality control was performed in two stages; pre-
sample (to exclude low quality variant calls prior to sample QC)
and post-sample (to remove additional monomorphic or low
coverage variants in the ﬁnal post-QC sample panel). During pre-
sample QC, variants were ﬁrst ﬁltered to restrict to coding and
splice site contexts according to the Oncotator annotation.
Subsequent ﬁltering was performed according to genotype
quality (95% at Quality Score ≥Q20), read depth (95% at ≥8),
GATK VQSR (99.9 tranche) and missing data (<5%). Based on the
ﬁltered variant set, samples were assessed for outlying genotype
call missingness, excess heterozygosity and discordant sex
information using PLINK 1.9.23 Divergent ancestry was identiﬁed
through Principal Component Analysis in conjunction with 1000
Genomes data24 (Supplementary Figure 1) and duplication/
relatedness were assessed using the SNPRelate Maximum Like-
lihood Estimation method.25 Samples with heterozygosity >3 ×
standard deviation of the mean and/or mixed ancestry were
excluded. After exclusion of samples that failed quality control,
ﬁnal post-sample variant ﬁltering was performed to exclude
monomorphic variants and those with >5% missing data. Outliers
from Hardy–Weinberg equilibrium in the non-aggressive set were
detected with GWASTools26 and removed at P < 10−5 (Fisher’s
exact test). After exclusion of data from 8 cases due to mixed
ancestry, high heterozygosity or insufﬁcient sequencing coverage,
the ﬁnal sample set consisted of 139 aggressive and 141 non-
aggressive cases, and 150,787 coding or splice site variants that
passed QC (Table 1, Supplementary Table 1, Supplementary
Table 2).
Testing for batch effects and case-case confounding
Confounding was assessed through principal component (PC)
analysis, using a general linear model to test the association of PCs
with the case and batch status. The ﬁrst 10 PCs were tested, with
no association found for either case or batch status. Differences in
genotype call rates between cases were assessed using PLINK
1.9.23 One-way ANOVA was performed to test for association of
‘missingness’ rate with sample preparation batch. Neither batch
effects nor case-case confounding were detected (Supplementary
Figure 2).
Variant and gene-based association tests
Association of individual variants with case status was tested using
logistic regression with Firth correction using the rv package27 in R
and a Bonferroni adjusted signiﬁcance threshold (P < 3.3 × 10−7,
for 150,757 tested variants).
To assess the potential association between gene-level burden
of rare disruptive variants with phenotype, potentially damaging
variants were grouped into two categories. Tier 1 (predicted
deleterious) were protein truncating variants (PTVs; frameshift
indels, stop gain and splice variants) and Tier 2 (predicted
damaging) all non-truncating variants with CADD score ≥20
(Supplementary Table 2).21 Rare variants were deﬁned as those
with MAF <1% in the healthy non-Finnish European population, as
reported by the Exome Aggregation Consortium (ExAC).28
Gene-level association analyses were performed separately on
Tier 1 only, or Tier1 and Tier 2 variants combined, using Fisher’s
exact test (PLINK 1.9) or SKAT-O.29 The exome-wide signiﬁcance
Table 1. Clinical characteristics of PrCa cases that passed quality
control
Non-aggressive Aggressive
Age range
≤54 0 51
55–59 0 88
60–64 56 0
65–69 50 0
≥70 35 0
M Stage
M0 141 0
M1 0 139
N Stage
N0 141 27
N1 0 63
Nx 0 49
T Stage
T1 84 8
T2 57 11
T3 0 67
T4 0 42
Tx 0 11
Gleason score
≤6 141 8
7 0 26
≥8 0 79
Unknown 0 26
M Stage indicates the presence or absence of distant metastases and N
Stage indicates nodal spread; 1= present, 0= absent, x= unknown. T
Stage refers to the tumour staging according to the TNM staging system
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threshold was set at P < 1.4 × 10−6, based on 17,658 tested genes
and 2 variant sets.
Gene set association analyses
Gene set analyses were performed separately on Tier 1 only, or
Tier1 and Tier 2 variants combined, using Bayesian Risk Index30,31
and SKAT-O29 methods. BROCA gene set analysis was conducted
based on the expanded BROCA cancer risk gene panel of 60
genes.32 DNA repair gene set analyses were performed using 177
curated DNA repair genes and pathway groupings.33 Hallmark
gene set analyses were conducted according to the 50 gene sets
curated to represent speciﬁc biological processes in the Molecular
Signature Database (MSigDB) Hallmark Gene Set Collection (http://
software.broadinstitute.org/gsea/msigdb/collections.jsp).34
GO term enrichment analysis
For GO term enrichment analysis, we selected genes with the
highest differential burden of disruptive (Tier 1 and Tier 2) variants
between aggressive and non-aggressive cases. Genes were ranked
based on collapsing burden count odds ratios (ORs) of >2 or <0.5
and ﬁltered with an additional criterion of a minimum count
difference of 3 disruptive variants between groups. The enrich-
ment analysis of biological processes and molecular functions was
performed using AmiGO,35 PANTHER Overrepresentation Test
(2016-07-15 release) and GO Ontology database annotation (2016-
10-27 release), applying a Bonferroni adjustment to correct for
multiple testing.
RESULTS
Study design and whole exome sequencing
To investigate the genetic signature of aggressive PrCa risk
through a case–case analysis, we performed extreme phenotype
sampling36 of patients from the UK Genetic Prostate Cancer Study
(UKGPCS), in which ~90% of patients had clinically presenting
disease at diagnosis.14 We selected 144 aggressive and 144 non-
aggressive cases for whole exome sequencing. All cases were of
self-reported European ancestry and unrelated. The criteria for
deﬁning aggressive PrCa cases were metastatic disease combined
with early age of onset ( <60 years), while the non-aggressive
cases were later onset (≥60 years) and had low risk clinical
presentation (Gleason score <7, tumour stage T1-2b, no nodal
spread or metastases).
After exclusion of data from 8 cases due to mixed ancestry, high
heterozygosity or insufﬁcient sequencing coverage, the ﬁnal
sample set consisted of 139 aggressive and 141 non-aggressive
cases (Table 1, Supplementary Table 1). In total, 150,787 quality
ﬁltered coding or splice site variants were called across these
samples, of which 97,800 were rare (minor allele frequency, MAF,
<1%). 4240 of the rare variants were predicted to be protein
truncating (Supplementary Table 2). The median number of rare
PTVs per individual was 29 (range 16–44), with no signiﬁcant
difference in overall PTV burden between aggressive and non-
aggressive phenotypes. The numbers of rare germline PTVs within
our sample cohort are in agreement with observations for the
general UK population.37
Variant and gene level association analyses
We ﬁrst assessed association of all coding variants individually and
collapsed at the gene level with the extreme phenotypes. Single
variant tests were conducted for all variants with no MAF ﬁlter
applied, whilst gene level burden tests were performed using rare
(MAF<1%) variants for Tier 1 (PTVs) or Tier 1 plus Tier 2 (non-
truncating variants with a CADD score ≥20) variants separately. As
expected due to the modest sample size, no individual variant or
gene was associated with aggressive status at a statistically signiﬁcant
level after adjustment for multiple testing (data not shown).
Bayesian analysis of rare variants in DNA repair genes
We subsequently conducted analyses at the gene set level, using
previously curated gene collections linked to either speciﬁc
biological pathways or disease in the literature. We have
previously shown that deleterious mutations in the original 22
gene BROCA panel of high and moderate risk genes involved in
cancer predisposition, primarily focussed on hormone-driven
breast and ovarian cancers,32 are associated with aggressive PrCa
in a familial cohort.11 In this study, we identiﬁed 22 rare Tier 1
mutations in the extended 60 gene BROCA panel (Table 2 and
Fig. 1). These mutations were present in 17 metastatic patients
(12.2%) and only 4 non-aggressive cases (2.8%). BRCA2 (5 cases;
2.9% of metastatic and 0.7% of non-aggressive cases), ATM (4
cases; 2.2% in metastatic patients and 0.7% in non-aggressive) and
NBN (4 mutations identiﬁed in 3 cases; 2.2% of metastatic cases
and no carriers among the non-aggressive cases) were the most
frequently mutated genes, with one metastatic patient a carrier of
two Tier 1 BROCA mutations, both in NBN. 17 of the Tier 1 BROCA
variants in our cohort have been previously reported in ExAC and/
or ClinVar, of which 13 are classiﬁed as pathogenic and 1 as likely
pathogenic. Five variants had not been reported before: p.K828fs
in ATM, p.Y1527* in ATR, p.R89fs in NBN, p.Q244* in PMS2 and p.
A1653fs in SLX4.
We observed strong evidence for enrichment of Tier 1 variants
within BROCA panel genes among cases with the aggressive
phenotype using the Bayesian Risk Index method30,31 (Global BF
= 32.5), which identiﬁed NBN and BRCA2 as the genes contribut-
ing most strongly to this enrichment (Fig. 2a). Enrichment of PTVs
among metastatic cases was conﬁrmed by both SKAT-O (P=
0.004) and Fisher’s exact test (two-tailed, P= 0.003). This associa-
tion remained with BRCA2 excluded from the panel (Global BF=
25.9, SKAT-O P= 0.009). Carriers of BROCA gene PTVs also
demonstrate reduced survival compared with non-carriers (P=
0.01, Supplementary Figure 3). When the BROCA panel analysis
was expanded to include Tier 2 variants alongside Tier 1, evidence
for differential burden between cohorts was no longer maintained
(Global BF= 2.8).
24 of the 60 genes in the BROCA panel are DNA repair genes; of
the 22 Tier 1 BROCA panel variants identiﬁed, 21 were within DNA
repair genes and only 1 in the remainder of the panel. These DNA
repair gene PTVs were identiﬁed across genes participating in a
number of different DNA repair pathways, with the Fanconi
Anaemia pathway, homologous recombination, DNA damage
response and mismatch repair all represented. We therefore
analysed an expanded set of 177 curated DNA repair genes,33 to
assess whether rare variants in additional genes with a role in DNA
repair may also contribute to predisposition towards an aggressive
disease phenotype. We identiﬁed 64 rare Tier 1 variants in 47
different DNA repair genes in our cohort, with 23.7% of aggressive
and 25.5% of non-aggressive cases harbouring one or more such
variants. This expanded DNA repair gene set showed no overall
evidence for association with the aggressive phenotype using
either Bayesian Risk Index or SKAT-O methods, whether restricting
the analyses to Tier 1 variants only (Global BF= 8.4, SKAT-O P=
0.66), or including both Tier 1 and Tier 2 (Global BF= 0.1, SKAT-O
P= 0.19).
As no evidence for association with the metastatic phenotype
was observed for the full set of curated DNA repair genes, we
further stratiﬁed the analyses by the primary process or pathway
each gene participates in. These analyses were performed for both
Tier 1 and Tier 1 plus 2 variants separately. We observed very
strong evidence for association between the homologous
recombination pathway and the metastatic phenotype (Tier 1&2
Global BF= 558, Fig. 2b, Supplementary Table 3); this association
was primarily driven by NBN, for which a Tier 1 or 2 variant was
observed in 8 metastatic patients (5.8%) and no non-aggressive
cases.
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Bayesian pathway analysis
To investigate additional biological processes that may contribute
towards development of the aggressive phenotype, we performed
a Bayesian Risk Index analysis using genes curated within the 50
MSigDB Hallmark gene set collections.34 We observed very strong
evidence for differential burden of rare Tier 1 and Tier 2 variants in
the HALLMARK_IL6_JAK_STAT3_SIGNALING gene set (genes up-
regulated by IL6 via. STAT3; global BF= 159.3) and strong
evidence for the HALLMARK_ANGIOGENESIS gene set (genes up-
regulated during formation of blood vessels; global BF= 84.5). The
genes contributing most strongly to these enrichments were
ACVRL1 and LUM respectively (Supplementary Table 4, Fig. 2c, d),
with ACVRL1 demonstrating a higher burden of damaging variants
in non-aggressive cases and LUM enriched among the metastatic
cohort (Supplementary Table 5). Within the HALLMARK_IL6_JAK_-
STAT3_SIGNALING gene set, genes with the highest burden of
damaging variants in the metastatic cases were IL1R2, IL9R,
MAP3K8 and TLR2, with ACVRL1 and CD36 most enriched in non-
aggressive samples. In the HALLMARK_ANGIOGENESIS gene set,
LUM, PRG2, ITGAV and VCAN demonstrated the greatest enrich-
ment in aggressive cases and JAG1, CCND2 and COL3A1 in non-
aggressive cases (Supplementary Table 6). The majority of other
Hallmark gene sets did not show clear evidence for association
with aggressive status, although we observed positive association
(BF= 3-20) for several additional processes (Supplementary
Figure 4). Scrutiny of individual genes demonstrating strong
evidence (Gene level BF ≥ 100) in the top models from any gene
set analysis highlighted 8 further genes (AXL, CHRNG, CP, DHRS2,
MTOR, PARK2, RYR1, WISP2) that may represent additional
candidates for differential susceptibility towards metastatic PrCa
(Supplementary Table 4, Supplementary Figure 4); the majority of
which also have previously been linked to angiogenesis in the
literature. These effects were primarily conferred through Tier 2
variants. Only two of the 10 genes identiﬁed through Bayesian
Risk Index analysis were enriched for rare mutations in metastatic
patients, with the remainder over represented for rare variants
among cases with indolent disease (Supplementary Table 5).
GO term enrichment analysis
To further interrogate wider biological processes that may
contribute towards the development of the aggressive phenotype,
we performed GO term enrichment analysis of genes with the
largest OR calculated from the Tier 1 and Tier 2 variant burden.
When including both genes with highest (>2.0) and lowest (<0.5)
OR for metastatic disease, we observed a 1.9-fold enrichment of
the term “extracellular matrix organisation” (GO:0030198, P=
0.025). Analysis of only the genes with lowest OR (higher burden
of variants in the non-aggressive cases) showed a 9.0-fold
enrichment of the term “ﬁbril organisation” (GO:0097435, P=
0.035). Further investigation of the 8 genes contributing to this
enrichment (ADAMTS3, LTBP2, MFAP5, COL5A1, CD36, RIPK3,
COL3A1 and GSN) revealed all to be involved in the collagen
metabolism and angiogenesis pathways apart from RIPK3, which is
involved in amyloid ﬁbril formation (Supplementary Table 7).
Similarly, restricting the analysis to only genes with high OR for
aggressive PrCa revealed a 1.3-fold enrichment in the term
“cellular component organisation” (GO:0016043, P= 0.012), a
higher hierarchy term containing the “extracellular matrix
organisation” category.
DISCUSSION
Prostate cancer demonstrates a heterogeneous clinical presenta-
tion; whilst the majority of patients present with intermediate
Table 2. Rare protein truncating variants in the BROCA gene set
Gene dbSNP ID Variant type Ref Alt Protein change ClinVar ExAC MAF (EUR) CADD Phenotype category
ATM Frameshift deletion A – p.K828fs – – 31 Non-aggressive
ATM rs587779834 Frameshift deletion G – p.V1268fs 5 4.5×10−5 28.3 Metastatic
ATM rs786204751 Nonsense C T p.Q1839* 4 – 46 Metastatic
ATM rs770641163 Nonsense C T p.R2993* 5|4 3.0×10−5 47 Metastatic
ATR Nonsense A T p.Y1527* – – 42 Metastatic
BRCA2 rs41293477 Nonsense T G p.L1053* 5 – 29.2 Non-aggressive
BRCA2 rs80359454 Frameshift deletion GAAA – p.E1493fs 5 – 29.6 Metastatic
BRCA2 rs80359470 Frameshift deletion AA – p.N1626fs 5 – 25.5 Metastatic
BRCA2 rs11571658 Frameshift deletion TT – p.L2092fs 5 1.5×10−5 24.6 Metastatic
BRCA2 rs80359752 Frameshift insertion – A p.T3085fs 5 – 36 Metastatic
CHEK2 rs587781269 Nonsense G A p.R95* 5 0 38 Non-aggressive
NBN rs587780100 Frameshift deletion TGTT – p.K233fs 5 4.7×10−5 35 Metastatic
NBN rs587776650 Frameshift deletion TTTGT – p.K219fs 5 3.2×10−5 35 Metastatic
NBN Frameshift deletion C – p.R89fs – – 8.3 Metastatic
NBN rs587781891 Frameshift deletion G – p.I41fs 5 – 28.3 Metastatic
PALB2 rs180177110 Nonsense G A p.R753* 5 4.5×10−5 35 Metastatic
PMS2 Nonsense G A p.Q244* – – 40 Metastatic
PRSS1 rs766199324 Frameshift deletion C – p.P164fs – 1.5×10−5 26 Metastatic
RAD51D rs786202750 Frameshift deletion A – p.T188fs 5 – 27 Metastatic
SLX4 Frameshift deletion C – p.A1653fs – – 20.5 Non-aggressive
SLX4 rs767631456 Frameshift deletion CT – p.S936fs – 4.5×10−5 24 Metastatic
XRCC2 rs776336749 Frameshift deletion T – p.H268fs 3 0 28.3 Metastatic
All Tier 1 variants identiﬁed for genes in the 60 gene BROCA panel are described, alongside case phenotype status. For each variant, the type of alteration,
consequence at the protein level and CADD score are provided. dbSNP identiﬁers, ClinVar clinical signiﬁcance score (5= pathogenic, 4= likely pathogenic, 3
= uncertain signiﬁcance) and minor allele frequency in ExAC non-Finnish Europeans are provided for variants present in the respective databases
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phenotype and indolent disease, an appreciable subset progress
to an advanced, poorer prognosis phenotype. Identiﬁcation of
more effective prognostic markers capable of distinguishing
these outcomes would help inform clinical management path-
ways. Whole exome or alternatively whole genome sequencing
provides great promise for the identiﬁcation of novel genetic
factors associated with PrCa aggressiveness, whether heritable or
somatically acquired. Based on the relative rates of indolent and
metastatic PrCa, higher penetrance germline variants predispos-
ing towards greater likelihood of developing metastases in PrCa
patients are likely to be predominantly rare. Extremely large
sample sizes may therefore be required to achieve sufﬁcient
statistical power to reliably detect these associations; in most
settings far beyond levels that are currently ﬁnancially viable.38
Statistical power in modest sized rare variant sequencing studies
of complex diseases may nevertheless be improved through the
selection of enriched cohorts representing extreme pheno-
types.36 Power can also be further improved through analysis
of the effects of multiple aggregated rare variants within the
same gene or sets of related genes.38 This approach does also
have notable limitations however; particularly that the inclusion
of a substantial proportion of benign variants or non-pathogenic
genes in the analysis can reduce the signal to noise ratio, in turn
potentially masking markers that are truly associated, and that
curation of sets of interlinked genes relies on scholarly evidence
that is inevitably incomplete and continually evolving. Restricting
sequencing itself to smaller panels of candidate genes is another
method frequently employed in sequencing studies; this
simultaneously reduces both the cost of sequencing, thereby
facilitating maximisation of sample size, and the magnitude of
the multiple testing burden. In contrast to whole exome
sequencing however, panel based approaches do not permit
examination of all known genes, and therefore restrict investiga-
tions to plausible candidate genes based upon more narrow a
priori hypotheses.
Our previous work has shown that the BROCA cancer risk gene
panel, designed primarily to evaluate hereditary breast and
ovarian cancer predisposition, is informative in stratifying PrCa
risk among individuals with strong family history of PrCa.11
Through the case–case analysis presented in this study, we further
demonstrate that rare germline PTVs in the now extended BROCA
panel are also enriched in metastatic patients compared with PrCa
cases with a non-aggressive clinical presentation. Furthermore,
these mutations were observed almost exclusively in the DNA
repair gene component of the panel. Overall, 12.2% of the
metastatic cases examined carried a protein truncating mutation
in a BROCA panel gene compared with 2.8% of non-aggressive
cases, with BRCA2, ATM and NBN (frequencies 2.9%, 2.2% and 2.2%
in metastatic patients respectively) being the most commonly
mutated genes among the aggressive cohort. The ﬁndings for
BRCA2 and ATM are largely in agreement with recent candidate
gene studies in castration resistant metastatic PrCa cases12,39 and
lethal PrCa cohorts13 of primarily European ancestry. The Bayesian
Risk Index method that we employed ranked NBN as the gene
within the BROCA panel for which PTVs contributed most strongly
towards the metastatic phenotype. Furthermore, separate ana-
lyses of individual DNA repair pathways indicated a likely
additional contribution by rare non-truncating NBN variants to
increased risk of metastases. These ﬁndings are consistent with
previous observations that carriers of a Slavic founder mutation
(rs587776650 / 657del5) in NBN40 experience signiﬁcantly higher
PrCa mortality,41 and demonstrates that additional rare NBN
variants, including missense variants, may increase the risk of
aggressive PrCa in the British population.
Although this study therefore provides further evidence that
germline variants within a handful of speciﬁc DNA repair genes
increase risk of aggressive PrCa,9–13,39 no signiﬁcant association of
rare truncating variants with metastatic disease was observed in
our analysis of an expanded set of 177 genes curated speciﬁcally
as contributing towards DNA repair.33 This suggests that only a
subset of speciﬁc DNA repair genes or pathways contribute
substantially to the predisposition towards the poor prognosis
phenotype, and that germline PTVs within any family members for
which association has not yet been established are likely to occur
at extremely low frequencies in the British population. The PTVs
we identiﬁed were observed across genes contributing to multiple
separate DNA repair pathways, in particular homologous recom-
bination and the Fanconi anaemia pathway. Stratiﬁcation of the
DNA repair gene set by pathway provided strong evidence for a
role by homologous recombination in increased susceptibility to
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Fig. 1 Proportion of rare PTVs identiﬁed in the BROCA gene set. a Relative frequencies of Tier 1 mutations identiﬁed in the combined sample
cohort by gene. In total, 22 rare protein truncating variants in BROCA panel genes were identiﬁed. b Proportion and relative frequencies of
germline BROCA panel mutation carriers among metastatic cases. 18 BROCA PTVs, representing 11 unique genes, were identiﬁed in 17
patients from the aggressive cohort (12.2%). One individual was a carrier for 2 BROCA PTVs, both in NBN. c Proportion and relative frequencies
of germline BROCA panel mutation carriers among non-aggressive cases. 4 BROCA PTVs, each in a unique gene, were identiﬁed in non-
aggressive cases (2.8%)
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development of metastases, with the association driven primarily
by NBN.
Whilst we observed a high rate of germline DNA repair gene
mutations among our metastatic cohort in comparison to non-
aggressive PrCa cases, the absence of these mutations in the
majority of the cohort implies that additional biological processes,
besides faulty DNA damage response and repair, could also be
instrumental in predisposition towards or protection against
metastatic disease. Rare germline coding variants in TET2 have
previously been reported to be enriched in aggressive PrCa cases
of African ancestry; however this association was ethnicity speciﬁc
and was not found for European ancestry individuals.42 Within our
cohort, we observed truncating TET2 mutations in 3 patients, all
non-aggressive, whilst Tier 2 variants were identiﬁed in one
additional metastatic and one non-aggressive case. A low
frequency missense variant in HOXB13 (rs138213197 / G84E) has
also been robustly demonstrated to increase risk of PrCa in
European ancestry populations and is associated with familial
clustering and younger age of diagnosis; however no association
with clinical presentation or survival has been demonstrated.43–45
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Fig. 2 Bayesian Risk Index gene set analysis results. a BROCA gene set. b Homologous Recombination Pathway gene set. c Hallmark IL6/JAK/
STAT Signalling gene set. d Hallmark Angiogenesis gene set. Analyses for differential burden of damaging variants between metastatic and
non-aggressive cohorts were conducted for variants with MAF < 1% using Tier 1 variants only (BROCA gene set), or Tier 1 & 2 combined
(Homologous Recombination Pathway and Hallmark gene sets). Each gene in the gene set was analysed as an individual region, with the top
10 genes included in the models depicted as rows in the plot, ordered according to gene level region Bayes Factor (BF). The gene regions or
combinations of regions for the top models (indexed by the numbers on the x-axis) are plotted in the columns. These columns have widths
proportional to and are ordered based on the posterior probability of the corresponding model. Global Bayes Factors for the entire gene set
are indicated above each plot
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The HOXB13 G84E variant was identiﬁed in 1 non-aggressive case
only in our study and no further Tier 1 or 2 HOXB13 variants were
identiﬁed within either cohort. These observations provide further
support that these two genes are unlikely to contribute
substantially towards increased risk of aggressive disease in
European ancestry populations.
We conducted further gene set analyses in an attempt to
identify additional genes that may inﬂuence prognosis in PrCa
patients. GO term enrichment analysis on genes displaying a
differential case–case burden of rare disruptive variants was
performed, which highlighted genes involved in extracellular
matrix organisation and remodelling, a key event in angiogen-
esis.46 Interestingly, we also found damaging variants in genes
associated with collagen ﬁbril formation enriched among the non-
aggressive cases, alluding to a possible protective function against
tumour invasiveness of certain defects in the extracellular matrix
organisation. In line with these observations, Bayesian Risk Index
analysis of hallmark gene sets in MSigDB demonstrated evidence
that disruptive germline variants in genes contributing towards
angiogenesis can distinguish patients with metastatic and
localised disease. This analysis selected two gene sets with high
evidence of differential burden between the extreme phenotypes
and highlighted two genes in particular driving these associations,
LUM and ACVRL1. Further inclusion of genes that demonstrated a
gene-level BF > 100 within any gene set analysis returns a total of
10 genes for consideration. The majority of these genes have
previously been reported to be linked to angiogenesis, prolifera-
tion and poor prognosis in multiple cancer types, especially
through modulation of TGF-ß signalling. Indeed, pharmacological
inhibitors of two genes (ACVRL1 and AXL) are currently the subject
of clinical trials in a range of tumour types as prospective anti-
angiogenic therapeutics.47,48
In keeping with the role of many of these genes in
developmental or homoeostatic processes, PTVs were observed
in only 2 of the 10 genes shortlisted through the Bayesian Risk
Index analysis, with Tier 2 variants accounting for 81 of the 88 rare
variants identiﬁed in these genes in our cohort. We also observed
differential enrichment of mutations within either the metastatic
or non-aggressive cohort for different genes, implying a
combination of potential deleterious and protective effects
towards tumour invasiveness. Two genes exhibited enrichment
of disruptive mutations in metastatic cases, LUM and AXL. LUM
codes for lumican, a collagen-binding protein found in interstitial
collagenous matrices throughout the body and implicated as an
inhibitor of angiogenesis49,50; disruptive mutations within LUM
would therefore be expected to facilitate tumour vasculature
formation. Suppression of AXL expression has been reported to
play a central role in the proliferation of disseminated PrCa cells in
bone marrow into metastatic lesions from a dormant state,51
representing a plausible route through which disruptive variants
in AXL could predispose individuals that develop PrCa towards a
metastatic phenotype. The remainder of genes identiﬁed were
enriched for mutations in non-aggressive rather than metastatic
cases, with many also demonstrating biologically plausible
rationale for how these variants could potentially confer a
protective effect against tumour migration. ACVRL1 (also known
as ALK1) is a cell surface receptor in the TGF-beta signalling
pathway which binds bone morphogenic protein (BMP)-9 and -10,
appears to be involved in developmental and angiogenic blood
vessel formation, and has been shown to be highly expressed in
the vasculature and stroma in a high proportion of prostate
tumours.52 Germline disruptive variants within ACVRL1 could
therefore in principle inhibit development of new tumour
vasculature and hinder the onset of metastases. Similarly, mTOR
is a known promoter of angiogenesis through the VEGF signalling
pathway and is frequently targeted for inhibition in human
tumours to exert anti-angiogenic activity.53 Also of note is the CP
gene, which codes for ceruloplasmin, the major copper-carrying
protein in the blood. Association between angiogenesis and
copper levels has been established, with elevated levels of
ceruloplasmin itself linked to development of metastases in rabbit
models.54 Disruptive mutations in CP could therefore feasibly be
protective against angiogenesis in PrCa. Other genes enriched for
mutations in patients with indolent disease include WISP2, a gene
that inhibits proliferation of vascular smooth muscle cells and has
been associated with invasion, metastasis and poor prognosis,
although opposing effects have been reported for different cancer
types,55,56 DHRS2, which stabilises p53 by inhibiting Mdm2 and
may be upregulated in breast tumour endothelium in comparison
to normal breast vasculature,57,58 and PARK2, a gene linked to
hereditary Parkinson’s disease that also demonstrates tumour
suppressor functions and might confer an inﬂuence on apoptosis
through modulation of mitophagy.59,60
The use of differential ages in the deﬁnition of our aggressive
and non-aggressive cohorts enabled us to maximise our power to
detect associations through the analysis of sample groups at the
extremes of the phenotypic spectrum of PrCa, however could also
represent a potential confounder. As 105 of the 120 deaths within
our sample cohort were PrCa speciﬁc, and no cause was recurrent
among the remaining 15 deaths, there would appear to be
minimal evidence of any overlapping associations with large effect
sizes against other disease phenotypes within our data. We cannot
completely exclude however that this could represent a potential
limitation of our study, whilst the use of age as a criterion in the
deﬁnition of aggressiveness also limits our ability to examine the
effect of mutation carrier status on age at onset; since carrier
status, aggressiveness, and age are all correlated. Nonetheless, this
study demonstrates that germline PTVs in speciﬁc DNA repair
genes occur signiﬁcantly more frequently among, and therefore
can be used to distinguish, PrCa patients likely to progress to
metastatic disease. In particular, mutations in the NBN, BRCA2 and
ATM genes are associated with development of an aggressive
clinical phenotype. Using gene-set enrichment analyses, we have
also found strong preliminary evidence that rare, predominantly
non-truncating germline variants predicted to affect protein
function in speciﬁc genes contributing to angiogenesis are
implicated in conferring either predisposition towards, or protec-
tion against, progression to metastatic disease in men who
develop PrCa. If validated in larger independent cohorts, or meta-
analyses of multiple studies, these genes would represent
prognostic markers that may aid identiﬁcation of PrCa patients
at high or low risk of developing invasive disease, who would
warrant distinct clinical management pathways. These genes
could also represent exciting novel targets for targeted therapies
tailored towards individual PrCa patients with aggressive pheno-
type. These initial ﬁndings therefore warrant follow-up in larger
cohorts to validate their potential role in predisposition toward
metastatic disease.
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